{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/atrial-fibrillation/goals-outcome-measures/qof-indicators/","result":{"pageContext":{"chapter":{"id":"8bf96582-45d8-507c-9772-4c1092b4bd6a","slug":"qof-indicators","fullItemName":"QOF indicators","depth":2,"htmlHeader":"<!-- begin field 46087857-5ccc-4df6-8d72-652d58d1070d --><h2>QOF indicators</h2><!-- end field 46087857-5ccc-4df6-8d72-652d58d1070d -->","summary":null,"htmlStringContent":"<!-- begin item 11b017da-c327-4ebb-b5d8-ab5cd5853e8f --><!-- begin field 6dc651eb-cec9-4659-8019-70000a24e9fa --><p><strong>Table 1.</strong> Indicators related to atrial fibrillation in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract.</p><table><thead><tr><th colspan=\"1\">Indicator</th><th colspan=\"1\">Points</th><th colspan=\"1\">Achievement thresholds</th></tr></thead><tbody><tr><td colspan=\"1\"><strong>AF001</strong> The contractor establishes and maintains a register of patients with atrial fibrillation.</td><td colspan=\"1\">5</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"1\"><strong>AF006</strong> The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)</td><td colspan=\"1\">12</td><td colspan=\"1\">40–90%</td></tr><tr><td colspan=\"1\"><strong>AF007</strong> In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated with anti-coagulation drug therapy</td><td colspan=\"1\">12</td><td colspan=\"1\">40–70%</td></tr><tr><td colspan=\"3\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">BMA and NHS Employers, 2018</a>]</td></tr></tbody></table><!-- end field 6dc651eb-cec9-4659-8019-70000a24e9fa --><!-- end item 11b017da-c327-4ebb-b5d8-ab5cd5853e8f -->","topic":{"id":"c61747eb-a307-5da3-9878-9e952f2e1246","topicId":"e42fc175-7ae7-44c7-b7ef-b58a14733e7e","topicName":"Atrial fibrillation","slug":"atrial-fibrillation","lastRevised":"Last revised in October 2020","chapters":[{"id":"15747365-1cc2-550f-ad60-639db7df4ff0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ced6fef-0141-5375-b1c4-37d2756e7678","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75cb268e-28e7-51c1-87dd-0a86fbc0616b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1390db2e-6367-52cb-9af5-792d2e4d9310","slug":"changes","fullItemName":"Changes"},{"id":"f65a3e88-8f57-5c09-867a-ba88262e838c","slug":"update","fullItemName":"Update"}]},{"id":"16591b01-3ee5-5b14-a7e2-7a5226294933","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f3967a51-562c-5a5b-b55a-02dd39bfcbe9","slug":"goals","fullItemName":"Goals"},{"id":"5a66a5f8-9497-5664-abc1-d16cfe63bdd4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ca3b265-f279-56a1-94f0-c0e96dbeaaff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8bf96582-45d8-507c-9772-4c1092b4bd6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"992b55c8-2134-5283-b0f7-34608af53bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"677bafba-be09-57b3-a169-096ee3aa3fa1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6e491b1-6724-5c59-b127-fc29812ea52f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dab901c7-1cc0-5253-a4e0-e5b5bc04ba5e","slug":"definition","fullItemName":"Definition"},{"id":"39c5efdc-48cc-5b0a-85d7-f7da2de67a25","slug":"causes","fullItemName":"Causes"},{"id":"211e1811-bd20-5cfb-b7b9-c06c3fd223a3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"96a3b3f8-183a-52b6-9909-a81f0fd999dd","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"fc0c1acd-3cda-53a5-85ae-be117589c6bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a1e6d67-1c9c-5ea9-a30c-006e32e641c7","slug":"diagnosis-of-atrial-fibrillation","fullItemName":"Diagnosis of atrial fibrillation"}]},{"id":"42efe54e-8ff7-5283-ad5f-7dabdd2dcdff","fullItemName":"Management","slug":"management","subChapters":[{"id":"a955511a-8fbf-5bf9-aa82-b0e634a6325b","slug":"management-of-af","fullItemName":"Scenario: Management of AF"}]},{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2c20504-f7cb-54cc-adc0-c0cb70ec0ccb","slug":"beta-blockers-except-sotalol","fullItemName":"Beta-blockers (except sotalol)"},{"id":"d02a47f9-0498-503c-9cb1-0c3f89766d4f","slug":"diltiazem-verapamil","fullItemName":"Diltiazem and verapamil"},{"id":"037e75e8-454f-5dcd-a0b8-3e9ff5a5b309","slug":"digoxin","fullItemName":"Digoxin"},{"id":"c0c53c1d-4cd9-5e70-8a01-3d5f59d213cb","slug":"anticoagulants","fullItemName":"Anticoagulants"},{"id":"49e47ec1-0743-51db-a133-a2eed45d0eb0","slug":"aspirin-clopidogrel","fullItemName":"Aspirin and clopidogrel"},{"id":"5cb461d2-9502-5698-a467-30edd459c1b3","slug":"amiodarone-not-initiated-in-primary-care","fullItemName":"Amiodarone - not initiated in primary care"},{"id":"0fae1520-f160-57a2-af90-5b46bb20bdf5","slug":"sotalol-not-initiated-in-primary-care","fullItemName":"Sotalol - not initiated in primary care"}]},{"id":"1048ec97-41b1-5f93-a54d-1f58a8a56528","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5fff0dc2-1e01-590e-a159-76736c6a2ac0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b4497d2f-172b-54a5-99c6-5cd92c8469ba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d1d9c4e5-758a-5a99-93e3-4d2099a68d60","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0b86c2fd-54d8-569a-a8a8-ccadd53c17a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e7ea1b2f-6198-53f7-b4f8-681296a03562","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3a114d83-bf8b-5507-b946-6af4f46c529e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5bbaf83e-cca2-55f4-a4c9-e6b808387a89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"16591b01-3ee5-5b14-a7e2-7a5226294933","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}